Clinical Trial Update: AK104 in Neoadjuvant Treatment of Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of AK104 for cervical cancer has completed, according to the Clinical Trials update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Cervical Cancer | Phase 2 | Status: COMPLETED